<DOC>
	<DOCNO>NCT01990885</DOCNO>
	<brief_summary>The purpose study evaluate safety different amount BL-7010 single oral administration repeat oral administration well-controlled celiac patient . Another purpose evaluate BL-7010 absorb body .</brief_summary>
	<brief_title>Safety Systemic Exposure Study BL-7010 Well-Controlled Celiac Patients .</brief_title>
	<detailed_description />
	<mesh_term>Celiac Disease</mesh_term>
	<criteria>Males female age 1875 year sign informed consent form Body mass index ( BMI ) 18.529.9 , inclusive Documented history biopsyproven celiac disease . Adherence glutenfree diet last 6 month prior randomization TG2 EMA antibody ( IgA ) negative Women childbearing potential men must agree use approved form contraception Ability willingness understand comply study procedure give write informed consent prior enrollment . IgA deficiency . History IgEmediated reaction gluten . Other food sensitivity allergy . Use oral steroid , biologics , immunosuppressant nonsteroidal antiinflammatory drug 6 month prior entry ( screen ) . Female subject pregnant breastfeeding . Clinically significant , concomitant gastrointestinal disease . Have clinically significant current historical medical problem diabetes mellitus , clinically significant cardiac arrhythmia , arteriosclerotic heart disease , renal insufficiency failure , autoimmune disease , history malignant melanoma history cancer ( exclude basal cell carcinoma ) within past 5 year prior screen . Subjects receive drug oral device , opinion Investigator , possible ineffective treatment drugs/oral device duration two week put subject medical risk Uncontrolled complication celiac disease . Any condition opinion Investigator place subject risk prevent protocol compliance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>